The Numbers That Define Ten Years of Clinical Access.
Every figure below is an audited operational record — documenting ten years of continuous clinical distribution across Kenyan county health systems and the East African Community.
Opening access to specialty and orphan medicine.
Specialized products in active institutional catalogue.
Kenyan county health networks plus cross-border supply.
Kenyan clinicians trained in keyhole PDA, VSD & MFO.
SHA-paid keyhole heart closures performed per year.
First keyhole closure without a cath lab (The Mater Hospital).
From pioneering specialty access to building Africa’s healthcare access infrastructure — ten years in four chapters
Medserv Africa begins: specialty supply for Kenyan institutions.
Starts training Kenyan cardiologists in keyhole PDA, VSD & MFO with LifeTech Scientific.
Overseas referrals fall ~63% (423 → 155); local specialty care grows across Kenya.
Revenue KES 117m → 217m (+85%); ROE 47% achieved under commercial discipline.
100+ SHA-paid keyhole procedures a year; Co-op Bank partnership; TheDOTMED in build.
Pioneers rare, orphan & specialty medicines in Kenya at scale.
A first: keyhole PDA closure without a cath lab, with The Mater Hospital.
Proctor-led camps (2 a year) give way to autonomous Kenyan-led procedures.
964 SKUs; 22 counties + Uganda; 64 customers; Kenya hosts ~7,944 EAC patients.
40 oncology products (Feb-27); TheDOTMED–Odoo (Dec-27); 47 counties + UG/TZ; KES 6.9bn.
Ten Years On, the Ripples of Access Reach Payers, Patients, and Doctors.
Medserv pioneered rare, orphan, and specialty medicines in Kenya at scale. When specialty medicine becomes predictable and verifiable, the economic and health outcomes ripple across the entire health system.
A Child with a Hole in the Heart Is Now Treated in Kenya.
An illustrative 5-stage patient journey showing how clinical training, global device sourcing, cold chain, and insurance reimbursement come together to save young lives.
- Families waited months for visiting overseas proctor-led surgical camps (held only twice a year).
- Or families were forced to fundraise and fly abroad; hospitals paid hefty international travel and facility fees.
- Clinical knowledge and procedural expertise left Kenya with the visiting surgical team once camps concluded.
- 5 Kenyan pediatric cardiologists trained since 2017 autonomously perform PDA, VSD, and MFO keyhole closures.
- 100+ procedures performed annually, funded directly through national SHA health insurance — no waiting for camps.
- Specialized interventional skills remain permanently in Kenya and are actively transferred to new medical fellows.
One Trusted Name, One Buyer Journey, and Six Capabilities.
Defined under our Hybrid Brand Strategy and Brand Equity Playbook. Medserv Africa provides master institutional trust, while TheDOTMED powers the unified buyer procurement workflow.
Accountable, regulated institutional supply — the established entity healthcare providers and hospital directors trust with rare, orphan, and specialty biopharmaceuticals.
One buyer-facing digital procurement journey — “We simplify healthcare procurement” through live catalogue search, instant digital quotations, and batch verification.
Rare, orphan, and oncology care accessible closer to the patient's home county.
DotLIFE links clinical education to partner-verified autonomous doctor competence.
Extending through licensed regional partners as regulatory and supply channels mature.
Tracking patient clinical value and financial health; reinvesting in dependable supply.
Leading Global Frameworks Explain Why the System Creates Lasting Value.
Applied by Medserv Africa management to validate economic additionality. Frameworks reflect established global business and healthcare research from Harvard Business School, Harvard Business Review, and the Impact Management Project.
| Framework & Source | Core Academic Concept | Medserv Africa Application | Verified Evidence |
|---|---|---|---|
| The Prosperity Paradox Christensen, Ojomo & Dillon (HBS), 2019 | Serving non-consumption creates enduring new markets that pull in skills, infrastructure, and regulatory frameworks. | Medserv served patients with zero local treatment options; DotSOURCE and DotGlobal made therapies available, pulling in specialists and cold chain. | First-registration dates; patients on therapy; new local specialists. |
| Creating Shared Value Porter & Kramer (HBR), 2011 | Generating economic value in a way that simultaneously produces value for society across products, value chains, and clusters. | Products: Medserv specialty portfolio. Value chain: DotSOURCE → DotSwift cold chain. Cluster: DotLIFE clinician skills and Kenya as an EAC healthcare hub. | On-time delivery rates; zero temperature excursions; inbound EAC patients. |
| Redefining Health Care Porter & Teisberg (HBS), 2006 | Value is defined as the clinical health outcomes achieved per dollar (or shilling) spent across the full care cycle. | DotPESA structures affordable procurement; DotMetrics measures all-in cost per patient course within fixed national SHA insurance budgets. | Payer cost per therapy cycle; patients treated per KES million budget. |
| Impact-Weighted Accounts Sir Ronald Cohen (2020); HBS IWA Project | Measuring and publishing social and health impact in auditable numerical accounts alongside standard financial profit. | DotMetrics tracks and publishes verified patient access metrics directly alongside company revenue, gross margin, and cash flows. | Annual partner-verified clinical access statement. |
| Five Dimensions of Impact Impact Management Project (IMP) | Systematic evaluation of What, Who, How Much, Contribution (additionality), and Risk across all interventions. | TheDOTMED digital transaction logs test additionality — evaluating outcomes compared to what would have occurred without Medserv intervention. | Dated procurement baselines and additionality telemetry. |
Further Clinical Impact Areas Scheduled for Formal Validation
Minimizing interrupted chemotherapy and biologic treatment cycles for chronic oncology patients via DotSwift replenishment.
Introducing price-competitive value biologics to widen institutional patient access by 20–50% within existing hospital formularies.
Eliminating falsified medicine risks and achieving zero temperature excursion throughout domestic distribution legs.
Establishing transparent, expedited Section 29 and orphan drug registration precedents with Kenya’s Pharmacy & Poisons Board.
From Proving Access in Kenya to Becoming Africa’s Healthcare Infrastructure.
Transitioning from pioneering clinical access into an unbroken, verified pan-African digital corridor serving all 47 Kenyan counties and cross-border regional corridors.
- KES 187m commercial revenue (FY2025).
- Active distribution in 22 of 47 counties + Uganda.
- 964 SKUs in catalogue; first 2 PPB registrations.
- 100+ keyhole heart procedures funded annually by SHA.
- TheDOTMED enterprise procurement engine in active deployment.
- KES 6.9bn revenue (representing 15% of addressable market).
- Full distribution across 47 Kenyan counties + Uganda & Tanzania.
- 176 registered specialty and oncology pharmaceuticals.
- 60% of regional B2B healthcare procurement transacted via TheDOTMED.
- ≥95% On-Time In-Full (OTIF) and critical-SKU availability rate.